- Antiviral drugs, which inhibit the development and replication of viruses in the body, have become essential in the treatment and management of various viral infections across both acute and chronic settings due to their targeted action, ability to reduce viral load, and role in preventing disease progression and transmission
- The escalating demand for antiviral drugs is primarily driven by the rising global prevalence of infections such as HIV, hepatitis, and influenza, increasing healthcare access in emerging economies, advancements in drug formulations, and growing awareness of early diagnosis and timely antiviral intervention
- North America dominated the antiviral drugs market with a share of 58.66% in 2024 due to well-established pharmaceutical industry, strong healthcare infrastructure, and significant public and private investment in antiviral research and treatment programs
- Asia-Pacific is expected to grow at the fastest CAGR of 6.7% in the antiviral drugs market during the forecast period due to rising healthcare awareness, improving healthcare infrastructure, and a growing burden of viral infections
- The influenza segment dominated the antiviral drugs market with the largest market share of 34.54% in 2024 as these indications are more prevalent globally
